Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
JCI accreditation is recognized globally
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
This facility marks a significant milestone in transforming the global food industr
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Subscribe To Our Newsletter & Stay Updated